Novartis AG vs Johnson & Johnson
NVS vs JNJ — side-by-side comparison from reported financials. NVS leads 7, JNJ leads 4 of 11 comparable metrics.
Novartis AG
NVS · Healthcare
$143.75+0.45%Solid
Johnson & Johnson
JNJ · Healthcare
$261.79+2.07%Mixed
| Metric | NVS | JNJ |
|---|---|---|
| Price | $143.75 | $261.79 |
| Market cap | $273B | $631B |
| Revenue (TTM) | $56.7B | $97.9B |
| Revenue growth | +9.1% | +5.6% |
| Net margin | 24.7% | 21.5% |
| Free cash flow | $16.8B | $22.2B |
| Net cash (debt) | ($41.4B) | ($27.8B) |
| 1-year price return | +9.7% | +37.0% |
| P/E | 20.3 | 29.9 |
| P/E vs own history (cheap-side %) | 46% | 16% |
| Dividend yield | 3.49% | 2.00% |
| Return on equity | 30% | 26% |
| Altman Z-score | 3.50 | — |
| CV checks passed | 11 of 11 | 10 of 11 |
| Employees | 75,267 | 140,800 |
Full résumé-style profiles: NVS CV · JNJ CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.